Trademark applications and grants for Clovis Oncology, Inc.. Clovis Oncology, Inc. has 29 trademark applications. The latest application filed is for "PROOF"
State Incorporated | DELAWARE |
Entity Type | CORPORATION |
Address | 5500 Flatiron Parkway, Suite 100 Boulder, COLORADO UNITED STATES 80301 |
Patent Application | Date |
---|---|
IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS 20210338656 - 17/231307 Lopes; Jared ;   et al. | 2021-11-04 |
High Dosage Strength Tablets of Rucaparib 20190099430 - 16/154038 Etter; Jeffrey | 2019-04-04 |
High Dosage Strength Tablets of Rucaparib 20180200260 - 15/920643 Etter; Jeffrey | 2018-07-19 |
Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity 20180163271 - 15/104684 Lin; Kevin | 2018-06-14 |
Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor 20160074399 - 14/784503 LAI; Mei ;   et al. | 2016-03-17 |
NCAGE Code | 63JV0 | CLOVIS ONCOLOGY, INC.!DBA CLOVIS ONCOLOGY |
CAGE Code | 63JV0 | CLOVIS ONCOLOGY, INC. CLOVIS ONCOLOGY |
S.A.M. Registration | 63JV0 [830871518] | CLOVIS ONCOLOGY, INC. CLOVIS ONCOLOGY |
SEC | 0001466301 | Clovis Oncology, Inc. of DELAWARE |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.